How Oxymetholone Affects LDL Cholesterol

Oxymetholone (anadrol) raises LDL through the 17-alpha-alkylated oral pathway shared by the rest of the oral class:

1. First-pass hepatic loading: The 17-alpha-alkyl modification means oxymetholone reaches the hepatocyte intact and in concentration. This downregulates hepatic LDL receptor expression, slowing LDL particle clearance from plasma.

2. Highest hepatic burden of the commonly used orals: Oxymetholone produces the most severe liver enzyme elevations of any oral in this catalogue. Hengge (2003, PMID 12815555) found 43% of patients on 150 mg/day and 25% on 100 mg/day had ALT, AST or GGT rise to more than five times baseline, versus 8% on placebo. A compound placing that much stress on hepatic function is placing a correspondingly heavy signal on hepatic lipoprotein handling.

3. Complex oestrogenic behaviour that does not protect lipids: Oxymetholone does not aromatise, yet it produces marked oestrogenic side effects, most likely through direct oestrogen receptor activity of the parent molecule rather than through conversion to oestradiol. That distinction matters here: hepatic LDL receptor upregulation depends on oestradiol acting on the hepatocyte, and there is no evidence that oxymetholone's oestrogenic side effect profile confers any equivalent lipid protection. Users should not assume anadrol bloat means anadrol is protecting their LDL.

4. HTGL-driven HDL collapse alongside: The measured HDL fall of 19 to 23 mg/dL reflects hepatic triglyceride lipase upregulation. LDL rising while HDL collapses is the standard oral pattern.

At 50 and 100 mg/day (Schroeder 2003, PMID 12388137, 12 weeks, randomised, 31 men aged 65-80):

• HDL cholesterol: -19 plus or minus 9 mg/dL at 50 mg/day (p equals 0.04) and -23 plus or minus 18 mg/dL at 100 mg/day (p equals 0.008)
• ALT: +72 plus or minus 67 U/L at 100 mg/day (p less than 0.001)
• LDL was not reported in this trial. That is a real gap, not an omission on our part.

What we can say about LDL:

• Glazer (1991, PMID 1929679) pooled the anabolic steroid literature and found a weighted average LDL rise of 36% across compounds. Oxymetholone is at the aggressive end of the oral class on every other hepatic endpoint, so it is unlikely to sit below that average.
• Thompson (1989, PMID 2915439) established that oral 17-alpha-alkylated administration is what drives LDL up (stanozolol +29% versus injectable testosterone -16%). Oxymetholone shares that structural feature.
• Webb (1984, PMID 6493049) documented an LDL to HDL ratio of 6.0 in bodybuilders on oral-containing stacks versus 2.2 off. Given the size of the measured HDL fall on oxymetholone, the ratio damage will be at least this severe.

Practical expectation at bodybuilding doses (50-100 mg/day):

• LDL up 25 to 40%, HDL down 40 to 60%, both within 3 to 4 weeks. Treat these as informed estimates rather than trial figures.

Timing: 3 to 4 weeks to plateau. Recovery over 8 to 12 weeks after stopping.

Baseline lipid panel and liver panel together: Oxymetholone is the compound where both go wrong at once, and the liver picture usually forces the decision before the lipid picture does.

On cycle:

• Check lipids and liver enzymes at week 3 to 4 of a typical 4 to 6 week run.
• Track the LDL to HDL ratio and non-HDL cholesterol. The measured 19 to 23 mg/dL HDL fall means calculated LDL via the Friedewald equation is less reliable here, so a direct LDL or ApoB is worth the extra cost.

The liver usually decides first:

• With roughly a quarter to nearly half of patients on 100 to 150 mg/day showing liver enzymes above five times baseline, an oxymetholone run is often ended by ALT rather than by LDL. Do not treat a passable lipid panel as permission to continue when transaminases are climbing.

Post-cycle: Recheck lipids and liver enzymes at 8 weeks after the last dose.

Dose and duration are the only reliable levers:

• Hengge (2003, PMID 12815555) found 100 mg/day was as effective as 150 mg/day for lean mass and body cell mass while producing less liver toxicity. If oxymetholone is being used at all, there is direct trial evidence that the higher dose buys nothing.
• Keep runs to 4 weeks where possible, 6 at the outside.

Do not stack with another oral: Both the hepatic and lipid effects are additive, and oxymetholone starts from the highest baseline burden in the class.

Supportive measures:

• Cardiovascular exercise 30 to 45 minutes, 4 to 5 times per week.
• Soluble fibre 10 to 25 g/day for LDL through bile acid sequestration.
• TUDCA and NAC are frequently used for hepatic support on anadrol. Neither has evidence for improving LDL, and neither should be treated as licence to extend the run.

Do not misread the bloat: Oxymetholone's oestrogenic side effects do not come from aromatisation and there is no reason to believe they confer the hepatic LDL receptor support that genuine oestradiol provides.

Further reading: TUDCA and NAC for liver protection: what the evidence says